T-Cypher Bio
PrivateLast Round
Seed
Feb 25, 2021
Total Funding Raised
$42.3M
Company Overview
T-Cypher Bio operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Seed round in February 2021.
T-Cypher Bio is a biotechnology company that develops a pipeline of novel, T-cell receptor (TCR)-based therapeutics for solid tumours, autoimmune, and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
T-Cypher Bio Comparables
Compare T-Cypher Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| T-Therapeutics | 88% | |
| Engimmune Therapeutics | 86% | |
| Enara Bio | 86% |
For institutional investors. Book with your work email.
T-Cypher Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Feb 25, 2021 | ||||
| Series A | Feb 25, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
T-Cypher Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oxford Science Enterprises | Series A, Seed |
| University of Oxford | Series A, Seed |
| Borealis Ventures | Series A, Seed |
| Rio Tinto Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 27, 2024
Grew 20% QoQ, from 25 to 30 employees.
- Apr 12, 2024
Grew 30% QoQ, from 23 to 30 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_offices_inNov 11, 2026
On Nov 11th '26, T-Cypher Bio Ltd expands its Oxford operations by relocating its headquarters to Abingdon Science Park in the United Kingdom, adding a 12,000-square-foot facility with laboratory and office space.
- attends_eventNov 3, 2026
T-Cypher Bio Ltd presents preclinical data on its TC25 and TC11 oncology programs in poster presentations at the 2026 SITC annual meeting in Arizona from Nov 4th–8th '26.
For institutional investors. Book with your work email.
T-Cypher Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about T-Cypher Bio's valuation, stock price, and market status.
Is T-Cypher Bio a public or private company?
T-Cypher Bio is a private company.
What is the current stock price of T-Cypher Bio?
T-Cypher Bio is a private company, so its shares have no public market price. Caplight tracks T-Cypher Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is T-Cypher Bio worth (valuation)?
Valuation information for T-Cypher Bio is not publicly available.
Can I buy T-Cypher Bio stock?
T-Cypher Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was T-Cypher Bio's last funding round?
T-Cypher Bio's most recent funding round was Seed on February 25, 2021.
Who are the main investors in T-Cypher Bio?
Key investors in T-Cypher Bio include Oxford Science Enterprises.
Will T-Cypher Bio IPO soon?
No public IPO plans have been announced for T-Cypher Bio.
How can I track T-Cypher Bio secondary market activity?
Caplight tracks bids, offers, and trades in T-Cypher Bio's shares on secondary markets.